公开(公告)号：US20230047296A1

公开(公告)日：2023-02-16

申请号：US17495115

申请日：2021-10-06

申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ,  ASTEX THERAPEUTICS LIMITED

发明人： Jeffrey K. KERNS ,  James Callahan ,  Hongxing Yan ,  Thomas Daniel Heightman ,  Charlotte Mary Griffiths-Jones ,  Alison Jo-Anne Woolford ,  Tindy Li ,  Ami Lakdawala Shah ,  Roderick S. Davis ,  David Norton ,  Jeffrey Charles Boehm ,  Paris L. Hamilton ,  Nicole Cathleen Goodwin ,  Yun Jin

IPC分类号： C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/10 ,  C07D403/14 ,  C07D413/10 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D267/14 ,  C07D249/18 ,  C07D233/60 ,  C07D487/08 ,  C07D451/02 ,  A61P9/00 ,  A61P25/00 ,  A61P11/00 ,  A61P27/00 ,  A61P35/00 ,  A61P37/00 ,  C07D233/64 ,  C07D255/04 ,  C07D273/01 ,  C07D405/10

摘要： The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

公开(公告)号：US10604509B2

公开(公告)日：2020-03-31

申请号：US15736075

申请日：2016-06-15

申请人： GlaxoSmithKline Intellectual Property Development Limited ,  Astex Therapeutics, Limited

发明人： Jeffrey K. Kerns ,  James Callahan ,  Thomas Daniel Heightman ,  Alison Jo-Anne Woolford ,  Ami Lakdawala Shah ,  Roderick S. Davis ,  David Norton ,  Jeffrey Charles Boehm ,  Nicole Cathleen Goodwin

IPC分类号： C07D417/10 ,  C07D403/10 ,  C07D249/04 ,  C07D249/18 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/10 ,  C07D403/14 ,  C07D413/10 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D267/14 ,  C07D233/60 ,  C07D487/08 ,  C07D451/02 ,  A61P9/00 ,  A61P25/00 ,  A61P11/00 ,  A61P27/00 ,  A61P35/00 ,  A61P37/00 ,  C07D233/64 ,  C07D255/04 ,  C07D273/01 ,  C07D405/10

摘要： Provided are aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.

公开(公告)号：US11059816B2

公开(公告)日：2021-07-13

申请号：US16468777

申请日：2017-12-11

申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ,  ASTEX THERAPEUTICS LIMITED

发明人： Anthony William James Cooper ,  Nicole Cathleen Goodwin ,  Charlotte Mary Griffiths-Jones ,  Thomas Daniel Heightman ,  Jeffrey K. Kerns ,  Hendrika Maria Gerarda Willems ,  Hongxing Yan

IPC分类号： A61K31/553 ,  A61P9/04 ,  A61P11/00 ,  C07D498/04 ,  C07D419/12 ,  C07D249/04 ,  C07D401/12 ,  C07D419/14 ,  C07D513/04

摘要： The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof:

公开(公告)号：US12091409B2

公开(公告)日：2024-09-17

申请号：US17350183

申请日：2021-06-17

申请人： ASTEX THERAPEUTICS LIMITED

发明人： Anthony William James Cooper ,  Nicole Cathleen Goodwin ,  Charlotte Mary Griffiths-Jones ,  Thomas Daniel Heightman ,  Jeffrey K. Kerns ,  Hendrika Maria Gerarda Willems ,  Hongxing Yan

IPC分类号： C07D249/04 ,  A61K31/4192 ,  A61K31/4402 ,  A61K31/55 ,  A61K31/553 ,  A61K31/554 ,  A61P9/04 ,  A61P11/00 ,  C07D401/12 ,  C07D413/12 ,  C07D417/12 ,  C07D419/12 ,  C07D419/14 ,  C07D471/04 ,  C07D498/04 ,  C07D513/04

CPC分类号： C07D419/12 ,  C07D249/04 ,  C07D401/12 ,  C07D419/14 ,  C07D498/04 ,  C07D513/04

摘要： The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof:

公开(公告)号：US20220089590A1

公开(公告)日：2022-03-24

申请号：US17350183

申请日：2021-06-17

申请人： GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED ,  ASTEX THERAPEUTICS LIMITED

发明人： Anthony William James Cooper ,  Nicole Cathleen Goodwin ,  Charlotte Mary Griffiths-Jones ,  Thomas Daniel Heightman ,  Jeffrey K. Kerns ,  Hendrika Maria Gerarda Willems ,  Hongxing Yan

IPC分类号： C07D419/12 ,  C07D249/04 ,  C07D401/12 ,  C07D419/14 ,  C07D498/04 ,  C07D513/04

摘要： The present invention relates to ether-linked triazole compounds, methods of making them, pharmaceutical compositions containing them and their use as NRF2 activators. In particular, the invention relates to compounds of Formula (I), and pharmaceutically acceptable salts thereof:

公开(公告)号：US20200079759A1

公开(公告)日：2020-03-12

申请号：US16675634

申请日：2019-11-06

申请人： GlaxoSmithKline Intellectual Property Development Limited ,  Astex Therapeutics Limited

发明人： Jeffrey K. KERNS ,  James Callahan ,  Hongxing Yan ,  Thomas Daniel Heightman ,  Charlotte Mary Griffiths-Jones ,  Alison Jo-Anne Woolford ,  Tindy Li ,  Ami Lakdawala Shah ,  Roderick S. Davis ,  David Norton ,  Jeffrey Charles Boehm ,  Paris L. Hamilton ,  Nicole Cathleen Goodwin ,  Yun Jin

IPC分类号： C07D403/10 ,  C07D267/14 ,  C07D249/18 ,  C07D233/60 ,  C07D487/08 ,  C07D451/02 ,  A61P9/00 ,  A61P25/00 ,  A61P11/00 ,  A61P27/00 ,  A61P35/00 ,  A61P37/00 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/10 ,  C07D403/14 ,  C07D413/10 ,  C07D471/04 ,  C07D487/04 ,  C07D498/04 ,  C07D233/64 ,  C07D255/04 ,  C07D273/01 ,  C07D405/10

摘要： The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as NRF2 regulators.